Citations

Showing 10 of 108094 citations.

Osteonecrosis in Inflammatory Bowel Disease: Clinical Features, Risk Factor Analysis, and Outcomes
Bakhshi, Zeinab , Yadav, Siddhant, Harmsen, William S. , Varayil, Jithinraj Edakkanambeth , Karls, Kevin A, Tremaine, William J., Loftus, Edward V. , Edakkanambeth Varayil, Jithinraj, Loftus, Edward V , Edakkanambeth Varayil, Jithinraj , Karls, Kevin A.

Mayo Clinic

Inflammatory Bowel Diseases | September 23, 2022 | Volume: 29 | Issue: 8 | Pages: 1223-1230

10.1093/ibd/izac198 | PMID 36149260 Get It

AbstractBackgroundAvascular necrosis (AVN) is a known adverse event associated with corticosteroid (CS) usage. Inflammatory bowel disease (IBD) is often treated with a CS for induction of remission. We sought to describe clinical features and outcomes of IBD patients with AVN.MethodsIn this retrospective, single-center, case-control study, patients with IBD who had a diagnosis of osteonecrosis, aseptic necrosis, or AVN from 1976 to 2009 were included, and each was matched with up to 2 controls (IBD but no AVN) on age, sex, IBD subtype, geographic area of residence, and date of IBD diagnosis. We abstracted risk factor data from the medical records. Conditional logistic regression was performed accounting for minor differences in age and date of first IBD visit to assess the relationship between putative risk factors and AVN, expressed as odds ratio and 95% confidence interval.ResultsEighty-five patients were diagnosed with IBD-AVN and were matched with 163 controls. The mean age at AVN diagnosis was 47.5 years. AVN was diagnosed a median of 12.2 years after IBD diagnosis, and the control group was followed for a median of 15 years after IBD diagnosis to ensure that they did not have AVN. Ten percent of patients with AVN did not have any CS exposure. History of arthropathy or estrogen use in Crohn’s disease and use of CS, osteoporosis, and history of arthropathy in ulcerative colitis were significantly associated with AVN.ConclusionsMost patients with IBD-AVN had multifocal involvement. Most had received CS, but many patients had other risk factors including arthropathy.
Pathophysiology and Management of Pulmonary Embolism
Shah, Ishan K., Merfeld, John, Chun, Jimy, Tak, Tahir , Merfeld, John M

Mayo Clinic

International Journal of Angiology | September 23, 2022 | Volume: 31 | Issue: 03 | Pages: 143-149

10.1055/s-0042-1756204 | PMID 36157092 Get It

Abstract Pulmonary embolism (PE) is one of the most common etiologies of cardiovascular mortality. It could be linked to several risk factors including advanced age. The pathogenesis of PE is dictated by the Virchow's triad that includes venous stasis, endothelial injury, and a hypercoagulable state. The diagnosis of PE is difficult and is often missed due to the nonspecific symptomatology. Hypoxia is common in the setting of PE, and the degree of respiratory compromise is multifactorial and influenced by underlying cardiac function, clot location, and ability to compensate with respiratory mechanics. Right ventricular dysfunction/failure is the more profound cardiovascular impact of acute PE and occurs due to sudden increase in afterload. This is also the primary cause of death in PE. High clinical suspicion is required in those with risk factors and presenting signs or symptoms of venous thromboembolic disease, with validated clinical risk scores such as the Wells, Geneva, and pulmonary embolism rule out criteria in estimating the likelihood for PE. Advancement in capture time and wider availability of computed tomographic pulmonary angiography and D-dimer testing have further facilitated the rapid evaluation and diagnosis of suspected PE. Treatment is dependent on clinical presentation and initially involves providing adequate oxygenation and stabilizing hemodynamics. Anticoagulant therapy is indicated for the treatment of PE. Treatment is guided by presence or absence of shock and ranges from therapeutic anticoagulation to pharmacologic versus mechanical thrombectomy. The prognosis of patients can vary considerably depending on the cardiac and pulmonary status of patient and the size of the embolus.
Artificial microRNA suppresses C9ORF72 variants and decreases toxic dipeptides in vivo
Cabrera, Gabriela Toro , Meijboom, Katharina E. , Abdallah, Abbas, Foster, Zachariah W. , Weiss, Alexandra , Wightman, Nicholas, Stock, Rachel , Gruntman, Alisha M. , Giampetruzzi, Anthony, Petrucelli, Leonard , Brown, Robert C., Mueller, Christian , Tran, Helen, Weiss, Alexandra, Gendron, Tania F. , Brown, Robert

Mayo Clinic

No container title available | September 23, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2081412/v1 Get It

Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects motor neurons, causing progressive muscle weakness and respiratory failure. The presence of an expanded hexanucleotide repeat in chromosome 9 open reading frame 72 (C9ORF72) accounts for most cases of familial ALS and frontotemporal dementia (FTD). To determine if suppressing expression of C9ORF72 gene products can reduce toxicity, we designed a set of artificial microRNAs (amiRNA) targeting the human C9ORF72 gene. Here we report that an AAV9-mediated amiRNA significantly suppresses expression of the C9ORF72 mRNA, protein, and toxic poly-dipeptides generated by the expanded repeat in the brain and spinal cord.
Cardiac arrest due to trimethoprim-sulfamethoxazole induced hyperkalemia – a case report
Sharma, Abhishek , Jhawar, Nikita , Khosla, Atulya Aman , Venegas, Carla , Jhawar, N

Mayo Clinic

No container title available | September 23, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1976368/v1 Get It

Abstract Background: Prescribing physicians must be aware of drug-drug interactions and exercise caution to prevent life-threatening electrolyte abnormalities. Here, we present a case of hyperkalemia-induced cardiac arrest in a patient treated with lisinopril with underlying chronic kidney disease and a recent course trimethoprim-sulfamethoxazole. We emphasize the need for awareness and vigilance when reconciling medications to thwart life-threatening consequences of even seemingly benign drug interactions. Case presentation: A 55-year-old male was brought to the emergency room after being found unresponsive and pulseless for an unknown period due to cardiac arrest. Resuscitative efforts were successful in achieving return of spontaneous circulation after 15 minutes. In the emergency department, he was found to have a potassium level of 6.9. Further history obtained from the medical proxy revealed that the patient recently completed a course of trimethoprim-sulfamethoxazole, and he had underlying past medical history of chronic kidney disease and hypertension requiring treatment with lisinopril. The patient was subsequently transferred to the intensive care unit for neuroprognostication after arrest, continuous renal replacement therapy, and pressor support. Workup to investigate other causes of his arrest was unremarkable, leaving drug-induced hyperkalemia as the leading diagnosis made by exclusion. Conclusions: We underscore the need to recognize drug interactions when prescribing new medications and the potential complications they may have in patients with particular risk factors. In this case, our patient had underlying chronic kidney disease and hypertension requiring management with lisinopril. The addition of TMP-SMX precipitated life-threatening hyperkalemia which caused his cardiac arrest. We underscore the importance of preventing dangerous arrhythmias through detailed medication reconciliations and diligence when prescribing new medications to prevent adverse interactions.
Evaluation of Treatment Effect in Underrepresented Population in Cancer Trials: Discussion with International Regulators
Sridhara, Rajeshwari , Marchenko, Olga , Barksdale, Elizabeth , Gwise, Thomas, Hess, Lorenzo , Mandrekar, Sumithra J. , Rantell, Khadija , Raven, Andrew, Shen, Yuan-Li, Tendler, Craig , Theoret, Marc R. , Jiang, Qi , Chen, Jie , Dreyer, Nancy A , Fashoyin-Aje, Lola , Garrett‐Mayer, Elizabeth , Gormley, Nicole , Pignatti, Francesco , Raven, Andrew, Singh, Harpreet, Pazdur, Richard M.

Mayo Clinic

Statistics in Biopharmaceutical Research | September 23, 2022 | Volume: 15 | Issue: 2 | Pages: 450-456

10.1080/19466315.2022.2128404 Get It

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
Abramson, Jeremy S. , Johnston, Patrick B. , Ibrahimi, Sami , Arnason, Jon , Glaß, Bertram , Mutsaers, Pim , Lunning, Matthew A. , Braverman, Julia , Liu, Fei Fei , Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro , Guo, Shien, Shi, Ling , Solomon, Scott R. , Liu, Fei Fei , Abramson, Jeremy S , Ibrahimi, Sami , Kamdar, Manali , Izutsu, Koji

Mayo Clinic

Blood Advances | September 23, 2022 | Volume: 6 | Issue: 23 | Pages: 5969-5979

10.1182/bloodadvances.2022008106 | PMID 36149968 Get It

Abstract Lisocabtagene maraleucel (liso-cel) has shown promising efficacy in clinical trials for patients with relapsed/refractory large B-cell lymphoma (LBCL). We present health-related quality of life (HRQOL) results from the TRANSFORM study, the first comparative analysis of liso-cel vs standard of care (SOC) as second-line therapy in this population. Adults with LBCL refractory or relapsed ≤12 months after first-line therapy and eligible for autologous stem cell transplantation were randomized 1:1 to the liso-cel or SOC arms (3 cycles of immunochemotherapy in which responders proceeded to high-dose chemotherapy and autologous stem cell transplantation). HRQOL was assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire – 30 items and the Functional Assessment of Cancer Therapy-Lymphoma subscale. Patients with baseline and ≥1 postbaseline assessment were analyzed (liso-cel, n = 47; SOC, n = 43). The proportion of patients with meaningful improvement in global health status/quality of life (QOL) was higher, whereas deterioration was lower in the liso-cel arm vs SOC arm from day 126 to month 6. Mean change scores showed meaningful worsening in global health status/QOL at month 6, fatigue at day 29 and month 6, and pain at month 6 with SOC; mean scores for other domains were maintained or improved in both arms. Time to confirmed deterioration favored the liso-cel arm vs SOC arm in global health status/QOL (median: not reached vs 19.0 weeks, respectively; hazard ratio, 0.47; 95% confidence interval, 0.24-0.94). HRQOL was either improved or maintained from baseline in patients with relapsed/refractory LBCL in the liso-cel arm vs SOC arm as second-line treatment. This study is registered at clinicaltrials.gov as #NCT0357531.
Imaging of the Bulbourethral (Cowper) Gland: Abnormalities and Differential Diagnosis
Takahashi, Hiroaki , Potretzke, Theodora A. , Kawashima, Akira , Cheville, John C. , Masuoka, Sota , Kawashima, Akira , Potretzke, Theodora , Takahashi, Hiroaki , Kim, Bohyun

Mayo Clinic

RadioGraphics | September 23, 2022 | Volume: 42 | Issue: 7 | Pages: 2037-2053

10.1148/rg.220099 | PMID 36149823 Get It

Validation of MATCH score: a predictive tool for identification of patients with kelch-like protein-11 autoantibodies
Hammami, M Bakri , Rezk, Mohamed , Dubey, Divyanshu , Bakri, Hammami M , Dubey, Divyanshu

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | September 23, 2022 | Volume: 94 | Issue: 2 | Pages: 171-172

10.1136/jnnp-2022-329584 | PMID 36150843 Get It

Long-term outcomes of flow diversion for unruptured intracranial aneurysms: a systematic review and meta-analysis
Shehata, Mostafa , Ibrahim, Mohamed K. , Ghozy, Sherief , Bilgin, Cem , Jabal, Mohamed Sobhi , Kadirvel, Ramanathan , Kallmes, David F. , Shehata, Mostafa A, Ghozy, Sherief

Mayo Clinic

Journal of NeuroInterventional Surgery | September 23, 2022 | Volume: 15 | Issue: 9 | Pages: 898-902

10.1136/jnis-2022-019240 | PMID 36150896 Get It

Background Flow diverters have been widely used in clinical practice for more than a decade. However, most outcome data are limited to 1 year timepoints. This study aims to offer meta-analysis data on long-term (>1 year) safety and effectiveness results for patients with aneurysms treated with flow diverters. Methods PubMed, Web of Science, Embase, and SCOPUS were searched up to February 24, 2022 using the AutoLit platform. We included primary studies assessing the long-term outcomes for flow diverter devices to manage unruptured internal carotid artery aneurysms with a follow-up period of >1 year. The meta-analysis was carried out using Comprehensive Meta-Analysis software (CMA). Results Eleven studies were included in the meta-analysis. The pooled occlusion rates after flow diversion treatment for unruptured intracranial brain aneurysms were 77%, 87.4%, 84.5%, 89.4%, 96% for 1 year, 1–2 years, 2 years, 3 years, and 5 years follow-up, respectively. The in-stent stenosis rate was 4.8% and the retreatment rate for the long-term follow-up period was 5%. No delayed rupture of the aneurysm was reported, and there was one case of delayed ischemic stroke. The sensitivity analysis of the prospective studies showed a complete occlusion rate of 83.5% and 85.2% for 1 and 3 years of follow-up, respectively. Conclusion Flow diverters are safe and effective in short- and long-term follow-up and rarely cause serious delayed side effects.